US drugmaker Pfizer has denied allegations it overcharged for cancer medicines in South Africa following an investigation launched on Tuesday by the country’s competition watchdog into three drug companies.
The Competition Commission said it would investigate Aspen Pharmacare, Africa’s biggest generic drugmaker, Pfizer and Swiss-based Roche Holding on suspicion of charging too much for cancer medicines.
Pfizer denied it supplied its lung cancer product at the alleged price of ZAR152,000(US$11,800) and said it would cooperate fully with the investigation.
“We await the opportunity to be contacted by the Commission to clarify the pricing for this product,” it said in a statement.
The Commission said it had information that suggested Pfizer’s lung cancer treatment cost approximately US$12,000 for 250 mg when bought through an agent.
Aspen, a local company based in Durban, has also denied any wrongdoing, saying it had not increased its prices for medicines used to treat leukaemia beyond the margin approved by the South African health department.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK’s CMA Investigates Education Software Company for Market Abuse
May 14, 2024 by
CPI
Schumer Urges FTC Caution on Chevron’s $53B Hess Deal Over Gas Price Fears
May 14, 2024 by
CPI
Amazon Urges US Judge to Block FTC Probe into Data Preservation
May 14, 2024 by
CPI
Colorado Makes History: First State to Enact Comprehensive AI Legislation
May 14, 2024 by
CPI
Class Action Settlement Reached in Cheerleading Monopoly
May 14, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI